These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 26487343)

  • 1. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
    Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
    Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
    JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.
    Murnane PM; Celum C; Mugo N; Campbell JD; Donnell D; Bukusi E; Mujugira A; Tappero J; Kahle EM; Thomas KK; Baeten JM;
    AIDS; 2013 Aug; 27(13):2155-60. PubMed ID: 24384592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
    Murewanhema G; Malisheni M; Takah NF
    Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
    Baeten JM; Donnell D; Ndase P; Mugo NR; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kakia A; Odoyo J; Mucunguzi A; Nakku-Joloba E; Twesigye R; Ngure K; Apaka C; Tamooh H; Gabona F; Mujugira A; Panteleeff D; Thomas KK; Kidoguchi L; Krows M; Revall J; Morrison S; Haugen H; Emmanuel-Ogier M; Ondrejcek L; Coombs RW; Frenkel L; Hendrix C; Bumpus NN; Bangsberg D; Haberer JE; Stevens WS; Lingappa JR; Celum C;
    N Engl J Med; 2012 Aug; 367(5):399-410. PubMed ID: 22784037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
    Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
    JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.
    Wu L; Niu X; Brunelli MK; Mugwanya KK
    Curr HIV/AIDS Rep; 2024 Oct; 21(5):264-281. PubMed ID: 39120667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
    Trang TP; Dong BJ; Kojima N; Klausner JD
    Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invited commentary: every good randomization deserves observation.
    Westreich D; Edwards JK
    Am J Epidemiol; 2015 Nov; 182(10):857-60. PubMed ID: 26487342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
    Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
    J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
    Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.
    Ojeda VD; Amico KR; Hughes JP; Wilson E; Li M; Holtz TH; Chitwarakorn A; Grant RM; Dye BJ; Bekker LG; Mannheimer S; Marzinke M; Hendrix CW
    J Acquir Immune Defic Syndr; 2019 Sep; 82(1):34-40. PubMed ID: 31169769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
    Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
    Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preexposure prophylaxis for HIV infection among African women.
    Van Damme L; Corneli A; Ahmed K; Agot K; Lombaard J; Kapiga S; Malahleha M; Owino F; Manongi R; Onyango J; Temu L; Monedi MC; Mak'Oketch P; Makanda M; Reblin I; Makatu SE; Saylor L; Kiernan H; Kirkendale S; Wong C; Grant R; Kashuba A; Nanda K; Mandala J; Fransen K; Deese J; Crucitti T; Mastro TD; Taylor D;
    N Engl J Med; 2012 Aug; 367(5):411-22. PubMed ID: 22784040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.